Nanobiotix SA
PAR:NANO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nanobiotix SA
Long-Term Debt
Nanobiotix SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nanobiotix SA
PAR:NANO
|
Long-Term Debt
€91m
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
38%
|
|
|
Valneva SE
PAR:VLA
|
Long-Term Debt
€186.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Debt
€3.5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
-2%
|
|
|
Inventiva SA
PAR:IVA
|
Long-Term Debt
€51.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Long-Term Debt
$5.4m
|
CAGR 3-Years
68%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Long-Term Debt
€52.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
90%
|
|
Nanobiotix SA
Glance View
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
See Also
What is Nanobiotix SA's Long-Term Debt?
Long-Term Debt
91m
EUR
Based on the financial report for Dec 31, 2025, Nanobiotix SA's Long-Term Debt amounts to 91m EUR.
What is Nanobiotix SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
38%
Over the last year, the Long-Term Debt growth was 98%. The average annual Long-Term Debt growth rates for Nanobiotix SA have been 25% over the past three years , 17% over the past five years , and 38% over the past ten years .
